Musclepharm's ROA from the first quarter of 2022 to the first quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Musclepharm's ROA in the first quarter of 2022?
Musclepharm Corporation recorded a cumulative net loss of $-19 million during 12 months ending in the first quarter of 2022, resulting in a negative return on assets (ROA) of -169.56%.

However, within the Healthcare sector 1094 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2022 quarter, so far to 5473, from total ROA ranking in the fourth quarter of 2021 at 5737.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter	(Mar 31 2021) I. Quarter
Y / Y Total Assets Change	20.38 %	-13.78 %	10.71 %	-20.26 %	-32.75 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-19	-13	-3	1	3
Return On Assets (TTM)	-169.56 %	-118.55 %	-28.94 %	12.16 %	28.48 %
MSLP's Total Ranking	# 5473	# 5737	# 4051	# 582	# 171
Total Assets (TTM) in million	12	11	11	11	10
Seq. Total Assets Change	6.84 %	-0.89 %	3.39 %	9.96 %	-23.48 %
Seq. Net Income Change	-	-	-	-	-96.67 %

MSLP's 5 Years Annual ROA >> Back to MSLP Management Effectiveness >> Compare MSLP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 543
Sector	# 1095
Overall	# 5338

Return On Assets Statistics
High	Average	Low
28.4 %	-54.28 %	-282.29 %
(Mar 31 2021)		(Dec 31 2012)

Financial Statements
Musclepharm's Assets	$ 12 million	MSLP's Balance sheet
Musclepharm's Income	$ -6 million	Quarterly MSLP's Income Statement
MSLP's Income by Division		See MSLP's Income by Division

Annual Return On Assets	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2017) FY 2017	(Dec 31 2016) FY 2016
Y / Y Total Assets Change	-13.78 %	-10.58 %	-57.02 %	-0.79 %	-46.54 %
Total Assets in million	11	13	15	34	34
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-13	3	-19	-11	-3
Annual Return On Assets	-114.77 %	24.5 %	-130.17 %	-32.44 %	-10.2 %

MSLP's 5 Years Annual ROA >> Back to MSLP Management Effectiveness >> Compare MSLP ROA to its Competitors

More Return On Assets Ratios
MSLP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MSLP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MSLP's Competitors
Subscribers only: Roa for Musclepharm's Suppliers
Subscribers only: Return On Assets for MSLP's Customers

You may also want to know
MSLP's Roi	MSLP's Inventory Turnover Ratio	MSLP's Growth Rates	MSLP's Dividend Comparisons
	MSLP's Profitability Ratios	MSLP's Asset Turnover Ratio	MSLP's Dividend Growth
MSLP's Roe	MSLP's Valuation Ratios	MSLP's Financial Strength Ratios	MSLP's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2022, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:10:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.